Astellas Pharma Inc.
Important Dates
Astellas Pharma Inc.'s next confirmed earnings release is scheduled for November 4, 2026.
| Earnings Date | 11/4/2026 |
Share Statistics
As of March 31, 2025, Astellas Pharma Inc. has 1.79B shares outstanding.
| Shares Outstanding | 1.79B |
Financial Position
As of March 31, 2025, Astellas Pharma Inc. maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.13 |
| Quick Ratio | 0.21 |
| Debt / Equity | 54.94 |
Financial Efficiency
These figures cover the twelve months ended March 31, 2025.
| Employee Count | 14,476.25 |
Taxes
EUROver the twelve months ended March 31, 2025, Astellas Pharma Inc. recorded an income tax benefit of -94.85M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.
| Income Tax | -94.85M |
Balance Sheet
EURAs of March 31, 2025, Astellas Pharma Inc. holds 1.35B in cash and equivalents against 5.13B in total debt, resulting in a net debt position of 3.96B. Total book value stands at 9.33B, with working capital of 861.53M providing operational flexibility.
| Cash & Cash Equivalents | 1.35B |
| Total Debt | 5.13B |
| Net Debt | 3.96B |
| Equity (Book Value) | 9.33B |
| Book Value Per Share | 5.21 |
| Working Capital | 861.53M |
Cash Flow
EURThese figures cover the twelve months ended March 31, 2025.
| Capital Expenditures | -122.84M |
Stock Splits
Astellas Pharma Inc.'s most recent stock split took place on March 27, 2014 with a 1:5 split ratio.
| Last Split Date | 3/27/2014 |
| Split Ratio | 1:5 |